Literature DB >> 6108222

Relationship of propranolol pharmacokinetics to antihypertensive effect and beta-adrenergic blockade in the treatment of hypertension.

R T Krediet, A J Dunning, L Offerhaus.   

Abstract

The pharmacokinetics of propranolol in 16 hypertensive patients was compared after the first oral dose of 80 mg and during chronic treatment with 80 mg bd. The degree of beta-adrenergic blockade was estimated by the reduction in maximal exercise heart rate. No significant change in plasma half-life occurred and there was no correlation between the mean steady-state propranolol concentration and beta-adrenergic blockade or antihypertensive effect. A linear relationship was observed between the decrease in blood pressure and the reduction in heart rate during maximal exercise. Therefore, the antihypertensive effect of propranolol can be explained by it peripheral beta-adrenergic blocking properties.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6108222     DOI: 10.1007/bf00636790

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  Correlation of plasma propranolol concentration with therapeutic response in patients with angina pectoris.

Authors:  M Pine; L Favrot; S Smith; K McDonald; C A Chidsey
Journal:  Circulation       Date:  1975-11       Impact factor: 29.690

2.  EXERCISING TESTING IN ADULT NORMAL SUBJECTS AND CARDIAC PATIENTS.

Authors:  R A BRUCE; J R BLACKMON; J W JONES; G STRAIT
Journal:  Pediatrics       Date:  1963-10       Impact factor: 7.124

3.  Improved fluorimetric assay of plasma propranolol.

Authors:  L Offerhaus; J R van der Vecht
Journal:  Br J Clin Pharmacol       Date:  1976-12       Impact factor: 4.335

4.  Studies of the absorption and removal of propranolol in hypertensive patients during therapy.

Authors:  C A Chidsey; P Morselli; G Bianchetti; A Morganti; G Leonetti; A Zanchetti
Journal:  Circulation       Date:  1975-08       Impact factor: 29.690

5.  Plasma binding and the affinity of propranolol for a beta receptor in man.

Authors:  D G McDevitt; M Frisk-Holmberg; J W Hollifield; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1976-08       Impact factor: 6.875

Review 6.  Individualization of propranolol therapy.

Authors:  D G Shand
Journal:  Med Clin North Am       Date:  1974-09       Impact factor: 5.456

7.  Steady-state plasma concentrations of alprenolol in man.

Authors:  M D Rawlins; P Collste; M Frisk-Holmberg; M Lind; J Ostman; F Sjöqvist
Journal:  Eur J Clin Pharmacol       Date:  1974-08-23       Impact factor: 2.953

8.  Disposition of propranolol. V. Drug accumulation and steady-state concentrations during chronic oral administration in man.

Authors:  G H Evans; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

9.  Plasma propranolol levels in adults with observations in four children.

Authors:  D G Shand; E M Nuckolls; J A Oates
Journal:  Clin Pharmacol Ther       Date:  1970 Jan-Feb       Impact factor: 6.875

10.  Plasma concentrations of propranolol in patients with essential hypertension.

Authors:  A Lehtonen; J Kanto; T Kleimola
Journal:  Eur J Clin Pharmacol       Date:  1977-03-11       Impact factor: 2.953

View more
  6 in total

Review 1.  Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.

Authors:  Peer Tfelt-Hansen; Frederik Nybye Ågesen; Agniezka Pavbro; Jacob Tfelt-Hansen
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

2.  Pharmacokinetic and pharmacodynamic comparison of two doses of long acting propranolol (80 and 160 mg) in healthy subjects.

Authors:  B Flouvat; I Berlin; A Cournot; D Robinet; J Duchier; H Sarmini; A Rossi
Journal:  Br J Clin Pharmacol       Date:  1989-05       Impact factor: 4.335

Review 3.  Pharmacokinetics of long acting propranolol. Implications for therapeutic use.

Authors:  G S Nace; A J Wood
Journal:  Clin Pharmacokinet       Date:  1987-07       Impact factor: 6.447

4.  Liver drug metabolism and blood pressure response to a lipophilic and hydrophilic beta blocker.

Authors:  S Säkö; E A Sotaniemi; M Anttila
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1986 Apr-Jun       Impact factor: 2.441

5.  Comparison of the pharmacodynamic and pharmacokinetic profiles of single and multiple doses of a commercial slow-release metoprolol formulation with a new Oros delivery system.

Authors:  M J Kendall; D B Jack; K L Woods; S J Laugher; C P Quarterman; V A John
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

6.  A dose ranging study of atenolol in hypertension: fall in blood pressure and plasma renin activity, beta-blockade and steady-state pharmacokinetics.

Authors:  T Ishizaki; Y Oyama; T Suganuma; T Sasaki; H Nakaya; T Shibuya; T Sato
Journal:  Br J Clin Pharmacol       Date:  1983-07       Impact factor: 4.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.